Editas Medicine Inc (EDIT) Stock Analysis

Editas Medicine Inc (EDIT) is a publicly traded company in the HEALTHCARE sector. It trades at $2.82, carries a market capitalization of $512.56M. This page summarizes the public market data, fundamentals, and frequently asked questions for EDIT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Editas Medicine Inc currently has a Neutral sentiment score of 0.05.

About Editas Medicine Inc

Editas Medicine, Inc. is a leading clinical-stage genome editing company headquartered in Cambridge, Massachusetts, specializing in cutting-edge genomic therapies for serious genetic disorders. Utilizing its proprietary CRISPR technology, Editas is pioneering transformative treatments that have the potential to fundamentally change the management of various inherited conditions, enhancing patient care and outcomes. With a strong commitment to innovation and a diversified pipeline of therapeut...

GNG Research Analysis

GNG Research scores Editas Medicine Inc (EDIT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for EDIT.

Frequently Asked Questions

Does EDIT pay dividends?

Editas Medicine Inc (EDIT) does not currently pay a regular dividend.

What is EDIT's market cap?

Editas Medicine Inc (EDIT) has a market capitalization of $512.56M with a current stock price of $2.82.